Consensus statement from European experts on the diagnosis, management, and treatment of multiple myeloma: from standard therapy to novel approaches. (Q37761370)

From Wikidata

Jump to navigation Jump to search

scientific article published on August 2010

Language	Label	Description	Also known as
English	Consensus statement from European experts on the diagnosis, management, and treatment of multiple myeloma: from standard therapy to novel approaches.	scientific article published on August 2010

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20509769%20AND%20SRC:MED&resulttype=core&format=json

3 February 2020

1 reference

Europe PubMed Central

Consensus statement from European experts on the diagnosis, management, and treatment of multiple myeloma: from standard therapy to novel approaches (English)

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20509769%20AND%20SRC:MED&resulttype=core&format=json

3 February 2020

0 references

multiple myeloma

1 reference

based on heuristic

inferred from title

12

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20509769%20AND%20SRC:MED&resulttype=core&format=json

3 February 2020

14

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20509769%20AND%20SRC:MED&resulttype=core&format=json

3 February 2020

18

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20509769%20AND%20SRC:MED&resulttype=core&format=json

3 February 2020

Hermann Einsele

20

object named as

Hermann Einsele

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20509769%20AND%20SRC:MED&resulttype=core&format=json

3 February 2020

Antonio Palumbo

21

object named as

Antonio Palumbo

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20509769%20AND%20SRC:MED&resulttype=core&format=json

3 February 2020

19

object named as

Aaron Polliack

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20509769%20AND%20SRC:MED&resulttype=core&format=json

3 February 2020

author name string

Monika Engelhardt

1

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20509769%20AND%20SRC:MED&resulttype=core&format=json

3 February 2020

Martina Kleber

2

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20509769%20AND%20SRC:MED&resulttype=core&format=json

3 February 2020

Josefina Udi

3

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20509769%20AND%20SRC:MED&resulttype=core&format=json

3 February 2020

Ralph Wäsch

4

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20509769%20AND%20SRC:MED&resulttype=core&format=json

3 February 2020

Andrew Spencer

5

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20509769%20AND%20SRC:MED&resulttype=core&format=json

3 February 2020

Francesca Patriarca

6

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20509769%20AND%20SRC:MED&resulttype=core&format=json

3 February 2020

Stefan Knop

7

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20509769%20AND%20SRC:MED&resulttype=core&format=json

3 February 2020

Benedetto Bruno

8

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20509769%20AND%20SRC:MED&resulttype=core&format=json

3 February 2020

Martin Gramatzki

9

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20509769%20AND%20SRC:MED&resulttype=core&format=json

3 February 2020

Fortunato Morabito

10

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20509769%20AND%20SRC:MED&resulttype=core&format=json

3 February 2020

Martin Kropff

11

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20509769%20AND%20SRC:MED&resulttype=core&format=json

3 February 2020

Orhan Sezer

13

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20509769%20AND%20SRC:MED&resulttype=core&format=json

3 February 2020

Donald Bunjes

15

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20509769%20AND%20SRC:MED&resulttype=core&format=json

3 February 2020

Mario Boccadoro

16

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20509769%20AND%20SRC:MED&resulttype=core&format=json

3 February 2020

Christian Straka

17

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20509769%20AND%20SRC:MED&resulttype=core&format=json

3 February 2020

publication date

1 August 2010

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20509769%20AND%20SRC:MED&resulttype=core&format=json

3 February 2020

number of pages

20

1 reference

based on heuristic

inferred from page(s)

Leukemia & Lymphoma

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20509769%20AND%20SRC:MED&resulttype=core&format=json

3 February 2020

51

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20509769%20AND%20SRC:MED&resulttype=core&format=json

3 February 2020

8

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20509769%20AND%20SRC:MED&resulttype=core&format=json

3 February 2020

1424-1443

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20509769%20AND%20SRC:MED&resulttype=core&format=json

3 February 2020

State of the art therapy in multiple myeloma and future perspectives

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2010.487959

21 January 2018

Characterization of in vitro growth of multiple myeloma cells

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2010.487959

21 January 2018

160 years of multiple myeloma: progress and challenges

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2010.487959

21 January 2018

Monoclonal gammopathy of undetermined significance (MGUS) consistently precedes multiple myeloma: a prospective study

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2010.487959

21 January 2018

Multiple myeloma

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2010.487959

21 January 2018

Criteria for the classification of monoclonal gammopathies, multiple myeloma and related disorders: a report of the International Myeloma Working Group

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2010.487959

21 January 2018

International staging system for multiple myeloma

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2010.487959

21 January 2018

Multiple myeloma

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2010.487959

21 January 2018

High-dose chemotherapy with hematopoietic stem-cell rescue for multiple myeloma

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2010.487959

21 January 2018

Melphalan and prednisone plus thalidomide versus melphalan and prednisone alone or reduced-intensity autologous stem cell transplantation in elderly patients with multiple myeloma (IFM 99-06): a randomised trial

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2010.487959

21 January 2018

A comparison of allografting with autografting for newly diagnosed myeloma

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2010.487959

21 January 2018

Detection of renal impairment as one specific comorbidity factor in multiple myeloma: multicenter study in 198 consecutive patients.

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2010.487959

21 January 2018

Considerations in the treatment of multiple myeloma: a consensus statement from Italian experts

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2010.487959

21 January 2018

Pathogenesis and treatment of renal failure in multiple myeloma

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2010.487959

21 January 2018

Guidelines on the diagnosis and management of multiple myeloma 2005.

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2010.487959

21 January 2018

International Myeloma Working Group guidelines for the management of multiple myeloma patients ineligible for standard high-dose chemotherapy with autologous stem cell transplantation

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2010.487959

21 January 2018

Prevention of thalidomide- and lenalidomide-associated thrombosis in myeloma

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2010.487959

21 January 2018

Monitoring of renal function in cancer patients: an ongoing challenge for clinical practice.

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2010.487959

21 January 2018

Complete remission in multiple myeloma examined as time-dependent variable in terms of both onset and duration in Total Therapy protocols

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2010.487959

21 January 2018

Multiparameter flow cytometric remission is the most relevant prognostic factor for multiple myeloma patients who undergo autologous stem cell transplantation

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2010.487959

21 January 2018

Report of the European Myeloma Network on multiparametric flow cytometry in multiple myeloma and related disorders

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2010.487959

21 January 2018

Short-term thalidomide incorporated into double autologous stem-cell transplantation improves outcomes in comparison with double autotransplantation for multiple myeloma

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2010.487959

21 January 2018

Current multiple myeloma treatment strategies with novel agents: a European perspective

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2010.487959

21 January 2018

Antitumor activity of thalidomide in refractory multiple myeloma

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2010.487959

21 January 2018

Thalidomide in consecutive multiple myeloma patients: single-center analysis on practical aspects, efficacy, side effects and prognostic factors with lower thalidomide doses

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2010.487959

21 January 2018

Pulsed cyclophosphamide, thalidomide and dexamethasone: an oral regimen for previously treated patients with multiple myeloma

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2010.487959

21 January 2018

Thalidomide-dexamethasone as primary therapy for advanced multiple myeloma

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2010.487959

21 January 2018

Immunomodulatory drug CC-5013 overcomes drug resistance and is well tolerated in patients with relapsed multiple myeloma

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2010.487959

21 January 2018

Phase III clinical trial of thalidomide plus dexamethasone compared with dexamethasone alone in newly diagnosed multiple myeloma: a clinical trial coordinated by the Eastern Cooperative Oncology Group

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2010.487959

21 January 2018

Long-term results of response to therapy, time to progression, and survival with lenalidomide plus dexamethasone in newly diagnosed myeloma

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2010.487959

21 January 2018

Lenalidomide plus high-dose dexamethasone versus lenalidomide plus low-dose dexamethasone as initial therapy for newly diagnosed multiple myeloma: an open-label randomised controlled trial

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2010.487959

21 January 2018

Bortezomib therapy alone and in combination with dexamethasone for previously untreated symptomatic multiple myeloma

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2010.487959

21 January 2018

Autologous hematopoietic stem-cell transplantation for multiple myeloma

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2010.487959

21 January 2018

Role of autologous and allogeneic stem cell transplantation in myeloma

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2010.487959

21 January 2018

Impact of genetic abnormalities on survival after allogeneic hematopoietic stem cell transplantation in multiple myeloma.

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2010.487959

21 January 2018

Strategies to improve the outcome of stem cell transplantation in multiple myeloma

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2010.487959

21 January 2018

A new conditioning regimen involving total marrow irradiation, busulfan and cyclophosphamide followed by autologous PBSCT in patients with advanced multiple myeloma

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2010.487959

21 January 2018

Efficacy of diverse high-dose regimens followed by autologous peripheral blood stem cell transplantation in consecutive multiple myeloma patients: a single-centre analysis over a 12-year period

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2010.487959

21 January 2018

Melphalan plus total body irradiation (MEL-TBI) or cyclophosphamide (MEL-CY) as a conditioning regimen with second autotransplant in responding patients with myeloma is inferior compared to historical controls receiving tandem transplants with melph

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2010.487959

21 January 2018

A randomized trial of maintenance interferon following high-dose chemotherapy in multiple myeloma: long-term follow-up results

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2010.487959

21 January 2018

Comparison of 200 mg/m(2) melphalan and 8 Gy total body irradiation plus 140 mg/m(2) melphalan as conditioning regimens for peripheral blood stem cell transplantation in patients with newly diagnosed multiple myeloma: final analysis of the Intergrou

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2010.487959

21 January 2018

Autologous peripheral blood stem cell transplantation for multiple myeloma: a report of 259 cases from the Spanish Registry. Spanish Registry for Transplant in MM (Grupo Español de Trasplante Hematopoyético-GETH) and PETHEMA.

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2010.487959

21 January 2018

Transplantation as salvage therapy for high-risk patients with myeloma in relapse

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2010.487959

21 January 2018

Single versus double autologous stem-cell transplantation for multiple myeloma.

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2010.487959

21 January 2018

Characterization of clonogenic multiple myeloma cells

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2010.487959

21 January 2018

'Light-chain escape-multiple myeloma'-an escape phenomenon from plateau phase: report of the largest patient series using LC-monitoring

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2010.487959

21 January 2018

Maintenance treatment with interferon alpha-2b in multiple myeloma: a prospective randomized study from PETHEMA (Program for the Study and Treatment of Hematological Malignancies, Spanish Society of Hematology).

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2010.487959

21 January 2018

Maintenance therapy in multiple myeloma

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2010.487959

21 January 2018

Advances in biology of multiple myeloma: clinical applications

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2010.487959

21 January 2018

Maintenance therapy with thalidomide improves overall survival after autologous hematopoietic progenitor cell transplantation for multiple myeloma

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2010.487959

21 January 2018

Thalidomide maintenance following high-dose therapy in multiple myeloma: a UK myeloma forum phase 2 study

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2010.487959

21 January 2018

Low tolerance and high toxicity of thalidomide as maintenance therapy after double autologous stem cell transplant in multiple myeloma patients

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2010.487959

21 January 2018

Thalidomide and hematopoietic-cell transplantation for multiple myeloma

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2010.487959

21 January 2018

Results of a multicenter randomized phase II trial of thalidomide and prednisone maintenance therapy for multiple myeloma after autologous stem cell transplant

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2010.487959

21 January 2018

Maintenance therapy with alternate-day prednisone improves survival in multiple myeloma patients

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2010.487959

21 January 2018

Major tumor shrinking and persistent molecular remissions after consolidation with bortezomib, thalidomide, and dexamethasone in patients with autografted myeloma

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2010.487959

21 January 2018

Extended follow-up of a phase 2 trial of bortezomib alone and in combination with dexamethasone for the frontline treatment of multiple myeloma.

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2010.487959

21 January 2018

Phase II PETHEMA trial of alternating bortezomib and dexamethasone as induction regimen before autologous stem-cell transplantation in younger patients with multiple myeloma: efficacy and clinical implications of tumor response kinetics.

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2010.487959

21 January 2018

Induction of angiogenesis by normal and malignant plasma cells.

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2010.487959

21 January 2018

Pomalidomide (CC4047) plus low-dose dexamethasone as therapy for relapsed multiple myeloma

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2010.487959

21 January 2018

Evidence for a bone marrow B cell transcribing malignant plasma cell VDJ joined to C mu sequence in immunoglobulin (IgG)- and IgA-secreting multiple myelomas

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2010.487959

21 January 2018

Allografting with nonmyeloablative conditioning following cytoreductive autografts for the treatment of patients with multiple myeloma

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2010.487959

21 January 2018

Autologous stem cell transplantation followed by a dose-reduced allograft induces high complete remission rate in multiple myeloma

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2010.487959

21 January 2018

Bortezomib, tacrolimus, and methotrexate for prophylaxis of graft-versus-host disease after reduced-intensity conditioning allogeneic stem cell transplantation from HLA-mismatched unrelated donors

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2010.487959

21 January 2018

Oral melphalan and prednisone chemotherapy plus thalidomide compared with melphalan and prednisone alone in elderly patients with multiple myeloma: randomised controlled trial

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2010.487959

21 January 2018

Efficacy of melphalan and prednisone plus thalidomide in patients older than 75 years with newly diagnosed multiple myeloma: IFM 01/01 trial.

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2010.487959

21 January 2018

Bortezomib plus melphalan and prednisone for initial treatment of multiple myeloma

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2010.487959

21 January 2018

Melphalan, prednisone, and lenalidomide treatment for newly diagnosed myeloma: a report from the GIMEMA--Italian Multiple Myeloma Network

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2010.487959

21 January 2018

Improved survival in multiple myeloma and the impact of novel therapies

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2010.487959

21 January 2018

Relapse/Refractory myeloma patient: potential treatment guidelines.

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2010.487959

21 January 2018

A systematic review of the role of bisphosphonates in metastatic disease

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2010.487959

21 January 2018

The use of bisphosphonates in multiple myeloma: recommendations of an expert panel on behalf of the European Myeloma Network

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2010.487959

21 January 2018

American Society of Clinical Oncology 2007 clinical practice guideline update on the role of bisphosphonates in multiple myeloma

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2010.487959

21 January 2018

American Society of Clinical Oncology clinical practice guidelines: the role of bisphosphonates in multiple myeloma

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2010.487959

21 January 2018

Bisphosphonate-associated osteonecrosis of mandibular and maxillary bone: an emerging oral complication of supportive cancer therapy

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2010.487959

21 January 2018

Narrative [corrected] review: bisphosphonates and osteonecrosis of the jaws

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2010.487959

21 January 2018

Long-term efficacy and safety of zoledronic acid in the treatment of skeletal metastases in patients with nonsmall cell lung carcinoma and other solid tumors: a randomized, Phase III, double-blind, placebo-controlled trial

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2010.487959

21 January 2018

Reversibility of renal impairment in patients with multiple myeloma treated with bortezomib-based regimens: identification of predictive factors

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2010.487959

21 January 2018

Cystatin-C is an independent prognostic factor for survival in multiple myeloma and is reduced by bortezomib administration

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2010.487959

21 January 2018

Erythropoietin treatment in advanced multiple myeloma is associated with improved immunological functions: could it be beneficial in early disease?

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2010.487959

21 January 2018

Prevention of infections and thromboses after splenectomy or because of functional loss of the spleen

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2010.487959

21 January 2018

MicroRNA signatures in human cancers

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2010.487959

21 January 2018

Interleukin-6 dependent survival of multiple myeloma cells involves the Stat3-mediated induction of microRNA-21 through a highly conserved enhancer

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2010.487959

21 January 2018

MicroRNAs regulate critical genes associated with multiple myeloma pathogenesis

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2010.487959

21 January 2018

Identification of microRNA expression patterns and definition of a microRNA/mRNA regulatory network in distinct molecular groups of multiple myeloma.

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2010.487959

21 January 2018

Deregulation of microRNA expression in the different genetic subtypes of multiple myeloma and correlation with gene expression profiling.

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2010.487959

21 January 2018

MicroRNAs 15a and 16 regulate tumor proliferation in multiple myeloma

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2010.487959

21 January 2018

Early genetic events provide the basis for a clinical classification of multiple myeloma.

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2010.487959

21 January 2018

Cyclin D1 overexpression and response to bortezomib treatment in a breast cancer model

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2010.487959

21 January 2018

Recent major improvement in long-term survival of younger patients with multiple myeloma

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2010.487959

21 January 2018

Thalidomide-dexamethasone compared with melphalan-prednisolone in elderly patients with multiple myeloma

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2010.487959

21 January 2018

Oral melphalan, prednisone, and thalidomide in elderly patients with multiple myeloma: updated results of a randomized controlled trial.

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2010.487959

21 January 2018

Multicenter, randomized, double-blind, placebo-controlled study of thalidomide plus dexamethasone compared with dexamethasone as initial therapy for newly diagnosed multiple myeloma

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2010.487959

21 January 2018

Thalidomide and dexamethasone combination for refractory multiple myeloma

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2010.487959

21 January 2018

Hyperfractionated cyclophosphamide in combination with pulsed dexamethasone and thalidomide (HyperCDT) in primary refractory or relapsed multiple myeloma

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2010.487959

21 January 2018

The combination of bortezomib, melphalan, dexamethasone and intermittent thalidomide is an effective regimen for relapsed/refractory myeloma and is associated with improvement of abnormal bone metabolism and angiogenesis

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2010.487959

21 January 2018

Phase I-II trial of bortezomib plus oral cyclophosphamide and prednisone in relapsed and refractory multiple myeloma

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2010.487959

21 January 2018

Bortezomib or high-dose dexamethasone for relapsed multiple myeloma

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2010.487959

21 January 2018

Randomized phase III study of pegylated liposomal doxorubicin plus bortezomib compared with bortezomib alone in relapsed or refractory multiple myeloma: combination therapy improves time to progression

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2010.487959

21 January 2018

Lenalidomide plus dexamethasone for relapsed or refractory multiple myeloma

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2010.487959

21 January 2018

Lenalidomide plus dexamethasone for relapsed multiple myeloma in North America

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2010.487959

21 January 2018

Molecular mechanisms of novel therapeutic approaches for multiple myeloma

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2010.487959

21 January 2018

Understanding multiple myeloma pathogenesis in the bone marrow to identify new therapeutic targets

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2010.487959

21 January 2018

Prospective, randomized study of single compared with double autologous stem-cell transplantation for multiple myeloma: Bologna 96 clinical study

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2010.487959

21 January 2018

Identifiers

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q37761370&oldid=2109062049"